Using a stent graft to keep open failing arteriovenous dialysis grafts results in better patency and fewer reinterventions than angioplasty alone. Twelve-month results of the RENOVA trial were ...

Improvements in patency potentially enable uninterrupted dialysis and reduced use of central venous catheters. Drug-coated balloon angioplasty maintains patency better than standard balloon ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — In patients with dysfunctional hemodialysis arteriovenous fistulae, adding a drug-coated balloon to ...

Today, the U.S. Food and Drug Administration permitted marketing of two catheter-based devices designed to create a connection to veins and arteries in patients with chronic kidney disease who need ...

C.R. Bard scored FDA premarket approval for its Lutonix drug-coated balloon to treat a new indication: stenosis in the arteriovenous (AV) fistulae of patients with end-stage renal disease. The Lutonix ...

Compared with plain balloon angioplasty, treatment with a paclitaxel-coated balloon provides better patency and reduces the need for repeat procedures in dialysis patients with dysfunctional ...

Standard percutaneous transluminal angioplasty is the current recommended treatment for dysfunctional hemodialysis fistulas, yet long-term outcomes of this treatment are poor. Drug-coated balloons ...

Stent grafts may be more effective than balloon angioplasty in prolonging the function of stenosed arteriovenous access grafts and in lowering the likelihood of requiring additional interventions, ...

Covidien's Fortrex percutaneous transluminal angioplasty balloon catheter--Courtesy of Covidien Covidien ($COV) today announced FDA 510(k) clearance for its Fortrex ...

The US Food and Drug Administration (FDA) has cleared two minimally invasive, catheter-based devices to create arteriovenous (AV) fistulas percutaneously in patients with chronic kidney disease who ...